BHVN — Biohaven Ltd.
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1935979 ·
Last close
$13.50
Market Cap
$2.03B
52W High
$17.28
52W Low
$8.22
ADV30
2,937,965
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -130,428,000 | -130,532,000 | 466,406,000 | 273,074,000 | 336,906,000 |
| Dec 2025 | 0 | — | -142,734,000 | -145,555,000 | 451,447,000 | 229,957,000 | 399,375,000 |
| Sep 2025 | 0 | — | -169,382,000 | -173,443,000 | 409,123,000 | 184,847,000 | 426,283,000 |
| Jun 2025 | 0 | — | -211,701,000 | -198,147,000 | 550,415,000 | 165,797,000 | 415,828,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-594,232,000
Investing CF
$150,894,000
Financing CF
$617,764,000
CapEx
$-715,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-5.67
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-2,215,068,000
Inventory
—
Receivables
$2,597,000
ST Investments
$74,743,000
EBIT TTM
$-654,245,000
Pretax Income TTM
$-646,572,000
Interest Exp TTM
—
Analysts
17
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -745,378,000 | -738,822,000 | 451,447,000 | 399,375,000 | — | -609,438,000 |
| Dec 2024 | 0 | -885,111,000 | -846,422,000 | 615,107,000 | 191,671,000 | — | -582,453,000 |
| Dec 2023 | 0 | -436,051,000 | -408,168,000 | 513,212,000 | 85,237,000 | — | -331,725,000 |
| Dec 2022 | 0 | -567,932,000 | -570,279,000 | 661,783,000 | 123,012,000 | — | -297,689,000 |
TTM Snapshot
Revenues TTM
$443,853,000
NetIncome TTM
$-386,096,000
OpCashFlow TTM
$0
Assets (Latest)
$615,107,000
Forward EPS
$-1.94
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| GRFS | Grifols SA | $2.03B | $7.87 | — |
| HRMY | Harmony Biosciences Holdings, Inc. | $2.04B | $35.24 | — |
| ZLAB | Zai Lab Ltd | $2.06B | $18.27 | — |
| PVLA | PALVELLA THERAPEUTICS, INC. | $1.99B | $139.04 | — |
| ZBIO | Zenas BioPharma, Inc. | $1.98B | $31.44 | — |
News headlines (Yahoo Finance, 1h cache)
Biohaven Awarded $1 Million Over Alleged Trade Secret Violations by Avilar Therapeutics, RA Capital Management
2026-07-27 12:10 · Yahoo
Biohaven to Present New Clinical Data at ESMO Congress on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload
2026-07-20 11:30 · Yahoo
Bexorg Expands Leadership Team with Appointments of Bruce Car, Ph.D., as Chief Scientific Officer and Michael Fenn, Ph.D., as Chief Business Officer
2026-07-13 12:00 · Yahoo
ARPA-H puts $160M into bespoke drug therapies; Biohaven switches up scientific leadership
2026-07-10 08:04 · Yahoo
Is Biohaven’s (BHVN) R&D Shake-Up Quietly Redefining Its Late-Stage Pipeline Strategy?
2026-07-10 06:11 · Yahoo
Biohaven Announces Scientific Leadership Transitions
2026-07-09 21:00 · Yahoo
Biohaven (BHVN) Completes Enrollment in RISE3 Trial
2026-07-09 10:40 · Yahoo
BHVN Stock Builds Momentum Ahead Of Multiple H2 2026 Clinical Data Readouts
2026-07-09 00:12 · Yahoo
Why Wall Street Is Growing More Cautious on Biohaven (BHVN)
2026-07-06 17:20 · Yahoo
Biohaven Completes Enrollment in RISE 3 Pivotal Focal Epilepsy Study with Opakalim, a Selective Kv7.2/7.3 Activator
2026-06-30 11:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.